Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2019, Article ID 4625787, 12 pages
https://doi.org/10.1155/2019/4625787
Research Article

Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

1Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street, Cambridge, MA 02139, USA
2RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
3RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA 02452, USA
4Department of Haematology, Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, EBMT Paris Study Office, CEREST-TC, Saint-Antoine Hospital, Paris, France

Correspondence should be addressed to Keith L. Davis; gro.itr@sivadlk

Received 6 April 2018; Accepted 16 December 2018; Published 29 January 2019

Academic Editor: Francesco Dazzi

Copyright © 2019 Huamao Mark Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “World Cancer Research Fund International,” 2014, http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php. View at Publisher · View at Google Scholar
  2. N. Becker, “Epidemiology of multiple myeloma,” Recent Results in Cancer Research, vol. 183, pp. 25–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. European Cancer Observatory, “Cancer factsheet: Multiple myeloma nad immunoproliferative diseases,” 2014, http://eco.iarc.fr/EUCAN/Cancer.aspx?Cancer=39.
  4. M. A. Hussein, J. V. Juturi, and I. Lieberman, “Multiple myeloma: Present and future,” Current Opinion in Oncology, vol. 14, no. 1, pp. 31–35, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA), “Thalidomide for the treatment of multiple myeloma,” No. 28, 2004, http://www.cadth.ca/media/pdf/236_No28_thalidomide_preassess_e.pdf. View at Publisher · View at Google Scholar
  6. H. Ludwig, M. Beksac, J. Blade et al., “Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective,” The Oncologist, vol. 16, no. 4, pp. 388–403, 2011. View at Publisher · View at Google Scholar
  7. J.-L. Harousseau, M. Attal, H. Avet-Loiseau et al., “Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial,” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4621–4629, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Sonneveld, E. Asselbergs, S. Zweegman et al., “Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate,” Blood, vol. 125, no. 21, 2015. View at Google Scholar
  10. H. Einsele, P. Liebisch, and C. Langer, “Intravenous cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa trial),” Blood, pp. 114–59, 2009. View at Google Scholar
  11. J. L. Harousseau, H. Avet-Loiseau, J. Mary et al., “Bortezomib plus dexamethasone versus reduced-dose bortezomib plus thalidomide-dexamethasone as induction prior to autologous transplantation in newly diagnosed myeloma,” Haematologica, vol. 95, supplement 2, 2010. View at Google Scholar
  12. P. Moreau, T. Facon, M. Attal et al., “Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.,” Journal of Clinical Oncology, vol. 28, no. 15_suppl, pp. 8014–8014, 2010. View at Publisher · View at Google Scholar
  13. H. M. Lokhorst, B. Van Der Holt, S. Zweegman et al., “A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma,” Blood, vol. 115, no. 6, pp. 1113–1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. San Miguel, R. Schlag, N. K. Khuageva et al., “Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma,” The New England Journal of Medicine, vol. 359, no. 9, pp. 906–917, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. M. Fayers, A. Palumbo, C. Hulin et al., “Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials,” Blood, vol. 118, no. 5, pp. 1239–1247, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Benboubker, M. A. Dimopoulos, A. Dispenzieri et al., “Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma,” The New England Journal Of Medicine, vol. 371, no. 10, pp. 906–917, 2014. View at Google Scholar
  17. B. G. M. Durie, A. Hoering, M. H. Abidi et al., “Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial,” The Lancet, vol. 389, no. 10068, pp. 519–527, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. S. El Mahou, M. Attal, B. Jamard et al., “Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?” Clinical Rheumatology, vol. 25, no. 2, pp. 175–182, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Y. Kristinsson, O. Landgren, P. W. Dickman, Å. R. Derolf, and M. Björkholm, “Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003,” Journal of Clinical Oncology, vol. 25, no. 15, pp. 1993–1999, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Kumar, J. Ghosh, P. Ganessan, A. Gupta, R. Hariprasad, and V. Kochupillai, “High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: What predicts the outcome? Experience from a developing country,” Bone Marrow Transplantation, vol. 43, no. 6, pp. 481–489, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. National Cancer Institute, “Surveillance, Epidemiology and End Results Program: Cancer Stat Facts, Myeloma,” 2017, https://seer.cancer.gov/statfacts/html/mulmy.html.
  22. R. D. Harvey, “Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib,” Clinical Pharmacology: Advances and Applications, vol. 6, pp. 87–96, 2014. View at Publisher · View at Google Scholar
  23. D. S. Siegel, P. Richardson, M. Dimopoulos et al., “Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma,” Blood Cancer Journal, vol. 4, no. 2, p. e182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. P. G. Richardson, D. Siegel, R. Baz et al., “Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib,” Blood, vol. 121, no. 11, pp. 1961–1967, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Leleu, M. Attal, B. Arnulf et al., “Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02,” Blood, vol. 121, no. 11, pp. 1968–1975, 2013. View at Publisher · View at Google Scholar
  26. S. Lonial, C. S. Mitsiades, and P. G. Richardson, “Treatment options for relapsed and refractory multiple myeloma,” Clinical Cancer Research, vol. 17, no. 6, pp. 1264–1277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. J. P. Laubach, C. S. Mitsiades, A. Mahindra et al., “Management of Relapsed and Relapsed/Refractory Multiple Myeloma,” Journal of the National Comprehensive Cancer Network, vol. 9, no. 10, pp. 1209–1216, 2011. View at Publisher · View at Google Scholar
  28. M. Q. Lacy, S. R. Hayman, M. A. Gertz et al., “Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma,” Journal of Clinical Oncology, vol. 27, no. 30, pp. 5008–5014, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. K. Kumar, R. Vij, S. J. Noga et al., “Treating multiple myeloma patients with oral therapies,” Clinical Lymphoma, Myeloma & Leukemia, vol. 17, no. 5, pp. 243–251, 2017. View at Publisher · View at Google Scholar
  30. A. Palumbo, A. Chanan-Khan, K. Weisel et al., “Daratumumab, bortezomib, and dexamethasone for multiple myeloma,” The New England Journal of Medicine, vol. 375, no. 8, pp. 754–766, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Dimopoulos, A. Oriol, H. Nahi et al., “Daratumumab, lenalidomide, and dexamethasone for multiple myeloma,” The New England Journal of Medicine, vol. 375, no. 14, pp. 1319–1331, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Lonial, M. Dimopoulos, A. Palumbo et al., “Elotuzumab therapy for relapsed or refractory multiple myeloma,” The New England Journal of Medicine, vol. 373, no. 7, pp. 621–631, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. J. F. San-Miguel, V. T. Hungria, S. S. Yoon, M. Beksac, M. A. Dimopoulos et al., “Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial,” The Lancet Oncology, vol. 15, no. 11, pp. 1195–1206, 2014. View at Google Scholar
  34. B. Balasa, R. Yun, N. A. Belmar et al., “Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways,” Cancer Immunology, Immunotherapy, vol. 64, no. 1, pp. 61–73, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Richardson, C. Mitsiades, R. Schlossman et al., “The Treatment of Relapsed and Refractory Multiple Myeloma,” International Journal of Hematology, vol. 2007, no. 1, pp. 317–323, 2007. View at Publisher · View at Google Scholar
  36. D. M. Weber, C. Chen, R. Niesvizky et al., “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2133–2142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Dimopoulos, A. Spencer, M. Attal et al., “Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2123–2132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. P. G. Richardson, P. Sonneveld, M. W. Schuster, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators et al., “Bortezomib or high-dose dexamethasone for relapsed multiple myeloma,” The New England Journal of Medicine, vol. 352, no. 24, pp. 2487–2498, 2005. View at Google Scholar
  39. R. Z. Orlowski, A. Nagler, P. Sonneveld et al., “Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3892–3901, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Moreau, J. S. Miguel, P. Sonneveld, M. V. Mateos, and E. Zamagni, “Multiple Myeloma: ESMO Clinical Practice Guidelines,” Annals of Oncology, pp. 1–11, 2017. View at Google Scholar
  41. A. K. Nooka, E. Kastritis, M. A. Dimopoulos, and S. Lonial, “Treatment options for relapsed and refractory multiple myeloma,” Blood, vol. 125, no. 20, pp. 3085–3099, 2015. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Z. Orlowski, L. Gercheva, C. Williams et al., “A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma,” American Journal of Hematology, vol. 90, no. 1, pp. 42–49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Garderet, S. Iacobelli, and P. Moreau, “Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation,” Journal of Clinical Oncology, vol. 30, no. 20, pp. 2475–2482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. P. G. Richardson, S. Jagannath, P. Moreau et al., “A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and low-dose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): updated results,” Blood, vol. 120, no. 21, 2012. View at Google Scholar
  45. A. K. Stewart and A. Palumbo, “Treatment of relapsed multiple myeloma,” The New England Journal of Medicine, vol. 372, no. 18, pp. 1774-1775, 2015. View at Publisher · View at Google Scholar
  46. P. G. Richardson, V. T. M. Hungria, and S.-S. Yoon, “Panorama 1: a randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma,” ASCO Meeting Abstracts, vol. 32, supplement 15, p. 8510, 2014. View at Google Scholar
  47. D. E. Reece, E. Masih-Khan, E. G. Atenafu et al., “Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma,” British Journal of Haematology, vol. 168, no. 1, pp. 46–54, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman et al., “Improved survival in multiple myeloma and the impact of novel therapies,” Blood, vol. 111, no. 5, pp. 2516–2520, 2008. View at Google Scholar
  49. K. Anderson, S. Jagannath, A. Jakubowiak, S. Lonial, N. Raje, M. Alsina et al., “Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study,” Journal of Clinical Oncology, vol. 27, 8536 pages, 2009. View at Google Scholar
  50. M. Offidani, S. Bringhen, L. Corvatta et al., “Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: A case-matched study in advanced multiple myeloma,” European Journal of Haematology, vol. 78, no. 4, pp. 297–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. N. C. Munshi, K. C. Anderson, P. L. Bergsagel et al., “Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2,” Blood, vol. 117, no. 18, pp. 4696–4700, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. J. R. Jones, D. A. Cairns, W. M. Gregory et al., “Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial,” Blood Cancer Journal, vol. 6, no. 12, pp. e506–e506, 2016. View at Publisher · View at Google Scholar